大肠直肠癌筛检市场－2026-2031年预测

大肠直肠癌筛检市场正以 4.3% 的复合年增长率扩张，预计将从 2025 年的 157.94 亿美元增长到 2031 年的 203.29 亿美元。

大肠直肠癌 (CRC) 筛检市场是全球体外诊断和预防医学领域的重要组成部分，专注于检测结肠和直肠的癌前息肉和早期恶性肿瘤。由于 CRC 通常由腺瘤性息肉缓慢发展而来，因此筛检至关重要，为早期发现和预防提供了重要机会。该市场涵盖多种检测方式，包括粪便检验（粪便免疫化学检查、多靶点粪便 DNA 检测）、直接可视化技术（大肠镜检查、乙状结肠镜检查、胶囊内视镜检查）以及新兴的血液检测。市场成长的驱动力主要来自疾病负担的加重、人口结构的变化以及为提高筛检的可及性和依从性而不断加大的力度。

主要市场成长要素

市场扩张与全球大肠直肠癌发生率和疾病负担的不断加重密切相关。大肠直肠癌仍然是世界上最常见的癌症之一。其发病率的上升，尤其是在年轻人群和生活方式改变的地区，凸显了大规模筛检计画的紧迫性。这种流行病学趋势正在形成一个持续成长的筛检和治疗目标族群。

一些已确立且普遍存在的可改变风险因素进一步加剧了这一负担。主要的生活方式因素包括缺乏运动、低纤维高加工食品饮食、肥胖和吸烟。随着都市化和经济状况的变化，这些风险因素在全球范围内不断增加，导致人群整体风险水平升高，这进一步凸显了广泛筛检措施的必要性和合理性。

最重要的人口因素是世界人口老化。虽然大肠直肠癌 (CRC) 的发生率在年轻人中呈上升趋势，但50岁以后风险显着增加。 50岁及以上人口的持续成长，尤其是在已开发经济体，是筛检计画的重要目标族群。这种人口结构变化直接导致检测量增加，因为临床建议接受筛检的人数庞大且持续成长。

此外，公众意识的提高和系统性的公共卫生措施是关键的推动因素。政府主导的宣传活动、专业学会的指南以及教育工作提高了公众和医疗卫生人员对大肠直肠癌可预防性的认识。美国预防服务工作小组（USPSTF）等主要指引已将建议筛检年龄降低至45岁，扩大了目标人口。这些努力旨在消除公众意识障碍和社会偏见，从而直接提高筛检参与率。

市场区隔和不断发展的测试方法

市场特征是多种检测方式并存，每种方式各有优势，并根据患者偏好和医疗系统资源进行选择。粪便检验，特别是大便潜血试验（FIT），因其非侵入性、低成本和易用性而被广泛用于大规模筛检。多标靶粪便DNA检测（例如Cologuard）在检测晚期病变方面表现出高灵敏度，使其成为高端非侵入性检测选择。大肠镜检查仍然是诊断和治疗的黄金标准，能够发现病变并即时切除息肉。创新的重点在于提高非侵入性侦测的准确性和易用性，以及改善内视镜检查的体验和效率。

区域展望：北美市场表现强劲

预计北美将继续在全球大肠癌筛检市场占据重要份额。这一地位得益于其成熟的筛检基础设施、医护人员和公众的高度认知、多种筛检方式完善的报销机制以及较高的风险因素盛行率。主要企业的存在以及对新型检测方法的积极法规环境，进一步巩固了该地区作为创新和应用关键市场的地位。

竞争格局与策略重点

竞争格局包括大规模诊断公司、专业分子诊断公司和医疗设备製造商。竞争重点在于检测性能特征（灵敏度、特异性）、易用性、成本效益以及与临床工作流程的整合。策略创新主要集中在以下几个关键领域：

• 基于血液的液态生物检体：开发微创血液检测方法来检测循环肿瘤 DNA (ctDNA) 和其他与大肠直肠癌相关的生物标记物，由于血液采集方便，这可能会促进检测的普及。
• 推进粪便检验：提高早期癌症和进行性腺瘤的非侵入性检测的敏感度，同时保持特异性并减少假阳性。
• 内视镜技术的演进：高清成像和虚拟染色内视镜等影像技术的进步，以及人工智慧工具的进步，将提高大肠镜检查期间腺瘤的检出率。
• 数位化参与：利用数位平台和病患导航服务来提高筛检的启动率和完成率，尤其是在服务不足的人群中。

未来展望与战略考量

受人口结构变化和临床界对早期检测价值的广泛认可的推动，结直肠癌筛检市场预计将持续成长。未来，市场发展将受到以下因素的影响：透过更易于接受和使用的检测方法提高筛检参与率；以及转向基于风险分层的筛检方法，从而根据遗传、家族史和生活方式等因素提供个人化建议。

对于产业相关人员，策略成功取决于能否获得可靠的临床证据以支持新技术纳入指南，向支付方证明其成本效益，以及与医疗系统和公共卫生组织建立伙伴关係，从而实施综合筛检路径。此外，如何因应国际上不同的报销环境，以及如何解决筛检取得的健康差异，也将是关键挑战。作为癌症预防的基础，大肠直肠癌筛检市场的成长与全球公共卫生使命密不可分，即透过积极主动、实证的干预措施来降低癌症死亡率。

本报告的主要优势：

• 深入分析：获得主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
• 竞争格局：了解全球主要企业的策略倡议，并了解透过正确的策略进入市场的可能性。
• 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
• 可操作的建议：利用这些见解，在动态环境中做出策略决策，并开拓新的商机和收入来源。
• 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

以下是一些公司如何使用这份报告的范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

• 2021年至2025年的实际数据和2026年至2031年的预测数据
• 成长机会、挑战、供应链前景、法规结构与趋势分析
• 竞争定位、策略和市场占有率分析
• 按业务板块和地区（包括国家）分類的收入和预测评估
• 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策与法规
• 策略建议

第四章 技术展望

第五章 按筛检测试分類的大肠癌筛检市场

• 介绍
• 柔软性乙状结肠镜检查
• 粪便检验
• CT结肠成像
• 大肠镜检查
• 其他的

第六章 依最终用户分類的大肠癌筛检市场

• 介绍
• 独立诊断实验室
• 医院
• 其他的

第七章 各地区大肠癌筛检市场

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第八章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 合併、收购、协议和合作
• 竞争对手仪錶板

第九章：公司简介

• Eiken Chemical Co. Ltd
• Epigenomics Inc.
• Exact Sciences Corporation
• Polymedco Inc
• Hemosure Inc.
• F. Hoffmann-La Roche AG
• QuidelOrtho Corporation
• Siemens Healthineers AG
• Sysmex Corporation
• Olympus Corporation

第十章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 调查方法
• 简称

The colorectal cancer screening market, growing at a 4.3% CAGR, is expected to grow to USD 20.329 billion in 2031 from USD 15.794 billion in 2025.

The colorectal cancer (CRC) screening market is a critical segment within the global in-vitro diagnostics and preventive healthcare landscape, focused on the detection of precancerous polyps and early-stage malignancies in the colon and rectum. Screening is paramount, as CRC typically develops slowly from adenomatous polyps, providing a significant window for interception and prevention. The market encompasses a range of modalities, including stool-based tests (fecal immunochemical tests, multitarget stool DNA tests), direct visualization techniques (colonoscopy, sigmoidoscopy, capsule endoscopy), and emerging blood-based assays. Market growth is driven by a powerful combination of rising disease burden, demographic shifts, and increasing efforts to improve screening accessibility and adherence.

Primary Market Growth Drivers

The expansion of the market is fundamentally linked to the rising global prevalence and burden of colorectal cancer. CRC remains one of the most commonly diagnosed cancers worldwide. The increasing incidence, particularly notable in younger age cohorts and in regions undergoing lifestyle transitions, underscores the urgent need for scalable screening programs. This epidemiological trend creates a sustained and growing addressable population for screening tests and procedures.

This burden is exacerbated by well-established and pervasive modifiable risk factors. Key lifestyle drivers include sedentary behavior, dietary patterns low in fiber and high in processed foods, obesity, and tobacco use. The global increase in these risk factors, linked to urbanization and changing socio-economic conditions, contributes to a higher population-wide risk profile, further justifying and necessitating broad screening initiatives.

A paramount demographic driver is the global aging of the population. While CRC incidence is rising in younger adults, the risk escalates significantly after age 50. The expanding demographic of adults over 50, particularly in developed economies, represents the core target population for organized screening programs. This demographic shift ensures a large and growing pool of individuals for whom screening is clinically recommended, directly driving test volumes.

Furthermore, increasing awareness and structured public health initiatives are critical catalysts. Government-led campaigns, professional society guidelines, and advocacy work have elevated public and clinical understanding of CRC as a preventable disease. The lowering of recommended screening initiation age to 45 in key guidelines, such as those from the U.S. Preventive Services Task Force, has expanded the eligible population. These efforts aim to overcome barriers of awareness and stigma, directly translating into higher screening participation rates.

Market Segmentation and Evolving Modalities

The market is characterized by a multi-modal approach, each with distinct advantages catering to different preferences and healthcare system resources. Stool-based tests, particularly fecal immunochemical tests (FIT), are widely used for population-based screening due to their non-invasiveness, low cost, and ease of use. Multitarget stool DNA tests (e.g., Cologuard) offer higher sensitivity for detecting advanced lesions, representing a premium non-invasive option. Colonoscopy remains the gold standard diagnostic and therapeutic procedure, allowing for both detection and immediate polyp removal. Innovation is focused on improving the accuracy and user-friendliness of non-invasive tests and enhancing the experience and efficiency of endoscopic procedures.

Geographical Outlook: North American Market Strength

North America is expected to maintain a significant share of the global colorectal cancer screening market. This position is supported by a mature screening infrastructure, high awareness levels among both providers and the public, well-established reimbursement pathways for multiple screening modalities, and a high prevalence of risk factors. The presence of leading diagnostic companies and a proactive regulatory environment for novel tests further consolidates the region's role as a primary market for innovation and adoption.

Competitive Landscape and Strategic Focus

The competitive landscape includes large, diversified diagnostic corporations, specialized molecular diagnostics companies, and medical device firms. Competition centers on test performance characteristics (sensitivity, specificity), ease of use, cost-effectiveness, and integration into clinical workflows. Strategic innovation is directed toward several key areas:

• Blood-Based Liquid Biopsies: Developing minimally invasive blood tests that detect circulating tumor DNA (ctDNA) or other biomarkers associated with CRC, potentially improving compliance by offering a simple blood draw.
• Enhanced Stool Tests: Improving the sensitivity of non-invasive tests for early-stage cancer and advanced adenomas while maintaining specificity to reduce false positives.
• Endoscopic Technology: Advancing imaging capabilities (e.g., high-definition, virtual chromoendoscopy) and artificial intelligence tools to improve adenoma detection rates during colonoscopy.
• Digital Engagement: Utilizing digital platforms and patient navigation services to increase screening initiation and completion rates, particularly in underserved populations.

Future Trajectory and Strategic Considerations

The colorectal cancer screening market is poised for continued growth, propelled by demographic inevitability and the strong clinical consensus on the value of early detection. Future evolution will be shaped by the pursuit of higher screening participation rates through more acceptable and accessible tests, and the move towards risk-stratified screening approaches that personalize recommendations based on genetic, familial, and lifestyle factors.

For industry participants, strategic success will depend on generating robust clinical evidence to support new technologies in guidelines, demonstrating cost-effectiveness to payers, and forming partnerships with health systems and public health organizations to implement integrated screening pathways. Navigating diverse international reimbursement landscapes and addressing health equity in screening access will also be critical challenges. As a cornerstone of cancer prevention, the CRC screening market's growth is inextricably linked to the global public health mission of reducing cancer mortality through proactive, evidence-based intervention.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Colorectal Cancer Screening Market Segmentation

• By Screening Test
• Flexible Sigmoidoscopy
• Stool-based Tests
• CT Colonography
• Colonoscopy
• Others
• By End-User
• Independent Diagnostic Labs
• Hospitals
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. COLORECTAL CANCER SCREENING MARKET BY SCREENING TEST

• 5.1. Introduction
• 5.2. Flexible Sigmoidoscopy
• 5.3. Stool-based Tests
• 5.4. CT Colonography
• 5.5. Colonoscopy
• 5.6. Others

6. COLORECTAL CANCER SCREENING MARKET BY END-USER

• 6.1. Introduction
• 6.2. Independent Diagnostic Labs
• 6.3. Hospitals
• 6.4. Others

7. COLORECTAL CANCER SCREENING MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom
  • 7.4.4. Spain
  • 7.4.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. Japan
  • 7.6.4. South Korea
  • 7.6.5. Indonesia
  • 7.6.6. Thailand
  • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Eiken Chemical Co. Ltd
• 9.2. Epigenomics Inc.
• 9.3. Exact Sciences Corporation
• 9.4. Polymedco Inc
• 9.5. Hemosure Inc.
• 9.6. F. Hoffmann-La Roche AG
• 9.7. QuidelOrtho Corporation
• 9.8. Siemens Healthineers AG
• 9.9. Sysmex Corporation
• 9.10. Olympus Corporation

10. APPENDIX

• 10.1. Currency
• 10.2. Assumptions
• 10.3. Base and Forecast Years Timeline
• 10.4. Key Benefits for the Stakeholders
• 10.5. Research Methodology
• 10.6. Abbreviations